OSIMERTINIB

osimertinib 80 mg tablet, 30

OSIMERTINIB (12232T)

osimertinib 80 mg tablet, 30
12232T
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Initial treatment as first-line epidermal growth factor receptor tyrosine kinase inhibitor therapy

Restriction

Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Continuing treatment of first-line EGFR tyrosine kinase inhibitor therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 30 # of repeats: 5 DPMQ: $7,582.43 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Tagrisso